NS-863 Low Dose + NS-863 High Dose
Phase 2RecruitingDevelopment Stage
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Jul 1, 2026 → Dec 14, 2028
About NS-863 Low Dose + NS-863 High Dose
NS-863 Low Dose + NS-863 High Dose is a phase 2 stage product being developed by Nippon Shinyaku for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07441278. Target conditions include Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD).
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441278 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)